Fireside Chat, Conference Presentation, Interview
A Conversation with FDA Commissioner Stephen Hahn
- Society's return to normalcy depends on the speed of achieving a cure, which the agency frames as a "modern day space race" goal.
- The FDA maintains its regulatory independence, committing to decisions based strictly on sound science and data rather than political pressure or public relations.
- Regulatory staff are working around the clock to process the high volume of COVID-19 applications, remaining on track to meet current fiscal year user fee goals.
- Safety and efficacy assessments for additional antivirals in clinical trials will be conducted over the "next several months" using available data.
- Preliminary evidence indicates convalescent plasma is safe, with ongoing reviews to determine its efficacy as a treatment that could facilitate antibody studies.
- A readout from monoclonal antibody studies is expected in "late summer, early fall," with potential deployment intended to serve as a bridge between plasma use and vaccine availability.
- Clinical trials are being accelerated to obtain answers regarding treatments and vaccines "as soon as possible," with the hope of achieving a positive impact on mortality rates.
- Specific therapies including remdesivir, dexamethasone, and plasma are viewed as likely to reduce mortality if their death-reducing effects are confirmed by evidence.
- The medical community's improved capability to handle the disease is expected to provide an advantage as treatments and vaccines are deployed.
- A Health and Human Services team is managing logistics for vaccine distribution, including the supply of syringes, needles, and filled vaccines.
- Regulatory guidance is being developed to ensure vaccine clinical trials include vulnerable and underrepresented populations, such as older adults.
- The agency is reviewing flexibilities related to telemedicine and clinical trials to determine which permanent changes should be retained or improved.
- Real-world evidence gathered via an accelerator with the Reagan-Udall Foundations and NIH is expected to significantly influence future product decisions and represents a potential major breakthrough.
- Americans are encouraged to continue protective measures such as avoiding crowds, wearing masks, and practicing social distancing to safeguard vulnerable populations.
- The agency acknowledges that it cannot predict future outcomes without a "crystal ball" and remains focused on adapting to changing challenges.